Geneos Wealth Management Inc. Sells 3,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Geneos Wealth Management Inc. trimmed its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 47,096 shares of the company’s stock after selling 3,000 shares during the period. Geneos Wealth Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $492,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of TEVA. Bank of New York Mellon Corp raised its stake in Teva Pharmaceutical Industries by 1.6% in the first quarter. Bank of New York Mellon Corp now owns 1,875,394 shares of the company’s stock valued at $17,609,000 after buying an additional 28,920 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 12.3% during the first quarter. PNC Financial Services Group Inc. now owns 119,076 shares of the company’s stock valued at $1,118,000 after acquiring an additional 13,069 shares in the last quarter. MetLife Investment Management LLC raised its position in shares of Teva Pharmaceutical Industries by 4.7% in the 1st quarter. MetLife Investment Management LLC now owns 95,953 shares of the company’s stock valued at $901,000 after purchasing an additional 4,300 shares during the last quarter. BlackRock Inc. boosted its stake in Teva Pharmaceutical Industries by 3.7% in the 1st quarter. BlackRock Inc. now owns 41,648,716 shares of the company’s stock worth $391,081,000 after purchasing an additional 1,494,814 shares in the last quarter. Finally, Great West Life Assurance Co. Can grew its position in Teva Pharmaceutical Industries by 4.0% during the 1st quarter. Great West Life Assurance Co. Can now owns 420,533 shares of the company’s stock worth $4,137,000 after purchasing an additional 16,134 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Trading Down 4.1 %

Shares of NYSE:TEVA opened at $13.30 on Friday. The company has a market capitalization of $14.91 billion, a PE ratio of -28.30, a PEG ratio of 1.54 and a beta of 1.05. Teva Pharmaceutical Industries Limited has a 12-month low of $7.09 and a 12-month high of $14.47. The business has a 50 day moving average of $13.41 and a two-hundred day moving average of $11.15. The company has a current ratio of 1.02, a quick ratio of 0.69 and a debt-to-equity ratio of 2.23.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.25. The firm had revenue of $4.46 billion during the quarter, compared to analysts’ expectations of $3.97 billion. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. As a group, analysts forecast that Teva Pharmaceutical Industries Limited will post 2.28 EPS for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Mark Sabag sold 100,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total value of $1,352,000.00. Following the completion of the transaction, the executive vice president now owns 382,590 shares in the company, valued at approximately $5,172,616.80. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, EVP Mark Sabag sold 100,000 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total value of $1,352,000.00. Following the sale, the executive vice president now owns 382,590 shares of the company’s stock, valued at approximately $5,172,616.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Amir Weiss sold 31,766 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $12.37, for a total transaction of $392,945.42. Following the transaction, the chief accounting officer now owns 10,676 shares of the company’s stock, valued at $132,062.12. The disclosure for this sale can be found here. Insiders have sold a total of 390,738 shares of company stock valued at $5,132,766 in the last ninety days. 0.62% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have issued reports on TEVA shares. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 1st. Piper Sandler upgraded Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $12.00 to $19.00 in a research note on Monday, February 12th. HSBC assumed coverage on Teva Pharmaceutical Industries in a research note on Monday, December 18th. They set a “buy” rating and a $13.00 price target on the stock. The Goldman Sachs Group raised their price objective on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a “neutral” rating in a research note on Monday, February 5th. Finally, JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price on the stock in a research report on Friday, March 8th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average price target of $13.78.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.